Prometheus Biosciences
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com
Prometheus has shown the power of patient data in drug development. Built on the largest biobank for IBD, the company created a pipeline focused on UC/CD. Recent phase 2 data for their lead (PRA023) has validated their approach & serves as a template broadly.
The biobank got started >20 years ago at Cedars-Sinai. To match IBD patient samples w/ longitudinal clinical data. Discovering TL1A (lead target), expressed in ~30% of IBD patients. With lineage from a Dx company, Prometheus got started in 2016 to apply precision medicine to IBD.
PRA023 is a humanized mAB inhibiting TL1A for ulcerative colitis & Crohn’s disease. Overall, IBD affects ~2M patients in the US w/ patients often get drugs (anti-TNF/JAK) that do not target the underlying fibrosis. Prometheus used a targeted approach to treat the cause of UC/CD.
The biobank has well over 200K samples from ~20K patients collected over 2 decades. Something that needs to be done for every disease. Learn more about Prometheus here
https://www.prometheusbiosciences.com/